Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-13T06:41:54.002Z Has data issue: false hasContentIssue false
  • English
  • Français

Predictors of discontinuation on clozapine: a population study

Published online by Cambridge University Press:  13 June 2014

Steve MacGillivray ,
Steve J Cooper ,
Barbara English ,
Helen Millar  and
Brian Williams
Steve MacGillivray
Affiliation:
Division of Community Health Sciences and Lecturer in Mental Health, University of Dundee, Scotland
Steve J Cooper
Affiliation:
Department of Mental Health, Queen's University, Belfast, Northern, Ireland
Barbara English
Affiliation:
South and East Belfast trust
Helen Millar
Affiliation:
The Carseview Centre, Tayside Primary Care NHS Trust, Dundee, Scotland
Brian Williams
Affiliation:
Section of Public Health, Division of Community Health Sciences, University of Dundee, Scotland
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: A quarter of people with schizophrenia may be classed as ‘treatment-resistant’. Clozapine is an antipsychotic that holds significant potential benefit for this patient group and has recently been recommended by the National Institute for Clinical Excellence. Early discontinuation is common. This study explores the factors that predict such discontinuation.

Method: This retrospective cohort design was carried out on two hundred and one people with treatment resistant schizophrenia who had commenced clozapine between 1990 and 1997 identified from the Clozaril Patient Monitoring Service (CPMS) in Northern Ireland. Clinical and socio-demographic data was collected for three years before and after commencement on clozapine. Kaplan Meier survival analyses were conducted to identify differences in discontinuation rates according to a range of variables.

Results: Forty-five per cent of patients had discontinued before three years. No difference in rates were found between men and women, nor whether side-effects were reported or not Patients who had commenced clozapine at an older age had significantly higher cessation rates. People who had started clozapine at age 50+ were four times more likely to stop taking clozapine within three years than people aged between 17-29 years.

Conclusions: Differences in continuation rates may be due to a number of factors. Treatment resistance may increase with age, side-effects may worsen or patient willingness to tolerate such effects may reduce. Alternatively, clinicians may be more anxious about prescribing clozapine as levels of co-morbidity increase. Further research is required to identify precise reasons and develop interventions to reduce discontinuation rates among older patients.

Type
Original Papers
Information
Irish Journal of Psychological Medicine , Volume 20 , Issue 4 , December 2003 , pp. 115 - 118
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kane, JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia – an overview. Br J Psychiatry 1992; 160: 41–45.CrossRefGoogle Scholar
2.Wahlbeck, K, Cheine, M, Essali, MS. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). Oxford: Update Software, 1999.Google Scholar
3.Essock, SM, Hargreaves, WA, Dohm, FA. Clozapine eligibility among state hospital patients. Schizophrenia Bull 1996; 22: 15–25.CrossRefGoogle ScholarPubMed
4.Rascati, KL, Rascati, EJ. Use of clozapine in Texas mental health facilities. Am J Hospital Pharmacy 1993; 50(8): 1663–1666.Google ScholarPubMed
5.NICE. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia: National Institute for Clinical Excellence, 2002.Google Scholar
6.Lieberman, JA, Kane, JM, Safferman, AZet al.Predictors of response to clozapine. J Clin Psychiatry 1994; 55: 126–8.Google ScholarPubMed
7.Honer, WG, MacEwan, GW, Kopala, Let al.A clinical study of clozapine treatment and predictors of response in a Canadian Sample. Can J Psychiatry 1995; 40: 208–11.Google Scholar
8.Moeller, FG, Chen, YW, Steinberg, JLet al.Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry 1995; 7(4): 167–73.CrossRefGoogle ScholarPubMed
9.Avnon, M, Rabinowitz, J. Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. Br J Psychiatry 1995;167:760–764.CrossRefGoogle ScholarPubMed
10.Rosenheck, R, Chang, S, Choe, Yet al.Medication continuation and compliance: A comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000; 61(5): 382–386.CrossRefGoogle ScholarPubMed
11.Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of the literature. Clin Psychiatry 2002; 63(10): 892–909.CrossRefGoogle Scholar
12.Liberman, J, Chakos, M, Wu, Het al.Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry 2001; 49: 487–499.CrossRefGoogle Scholar